Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Johnson & Johnson, consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019
Loans and notes payable 3,451 3,870 11,701 17,979 12,771 4,424 4,305 4,297 3,766 3,798 3,173 3,350 2,631 5,078 5,332 2,190 1,202 2,299 1,719 1,708
Accounts payable 9,632 8,355 10,443 9,909 11,703 10,153 9,765 9,309 11,055 8,961 8,704 8,503 9,505 7,044 6,765 7,411 8,544 7,491 6,912 6,923
Accrued liabilities 10,212 10,101 10,605 11,204 11,456 11,953 12,607 13,006 13,612 13,812 10,485 13,223 13,968 9,629 8,940 8,384 9,715 9,004 8,297 7,946
Accrued rebates, returns and promotions 16,001 15,808 15,672 14,784 14,417 14,021 13,447 12,972 12,095 12,683 12,450 11,919 11,513 12,418 11,790 11,608 10,883 10,977 10,433 9,523
Accrued compensation and employee related obligations 3,993 3,337 3,062 2,231 3,328 3,006 2,717 2,098 3,586 3,146 2,709 2,060 3,484 3,012 2,313 2,166 3,354 2,886 2,291 1,986
Accrued taxes on income 2,993 2,899 2,687 4,266 2,127 1,986 1,980 1,708 1,112 2,161 1,200 1,877 1,392 1,666 1,632 1,930 2,266 2,505 1,701 1,025
Current liabilities 46,282 44,370 54,170 60,373 55,802 45,543 44,821 43,390 45,226 44,561 38,721 40,932 42,493 38,847 36,772 33,689 35,964 35,162 31,353 29,111
Long-term debt, excluding current portion 25,881 26,051 33,901 34,928 26,888 27,603 28,292 28,851 29,985 30,130 30,310 30,263 32,635 32,680 25,062 25,393 26,494 26,919 27,699 27,660
Deferred taxes on income 3,193 2,623 3,627 4,417 6,374 4,946 5,015 6,424 7,487 7,147 9,016 6,507 7,214 5,615 5,532 5,766 5,958 6,526 7,725 7,394
Employee related obligations 7,149 5,687 6,461 6,665 6,767 8,353 8,553 8,739 8,898 10,171 10,367 10,512 10,771 10,184 10,411 10,529 10,663 9,830 9,910 9,905
Long-term taxes payable 2,881 2,540 2,536 4,296 4,306 4,162 4,162 5,745 5,713 5,770 5,722 6,568 6,559 6,745 6,591 7,402 7,444 7,493 7,543 8,074
Other liabilities 13,398 13,562 14,582 14,421 10,437 9,918 10,524 10,497 10,686 11,177 12,724 11,941 11,944 12,149 11,034 10,944 11,734 11,381 10,102 8,928
Non-current liabilities 52,502 50,463 61,107 64,727 54,772 54,982 56,546 60,256 62,769 64,395 68,139 65,791 69,123 67,373 58,630 60,034 62,293 62,149 62,979 61,961
Total liabilities 98,784 94,833 115,277 125,100 110,574 100,525 101,367 103,646 107,995 108,956 106,860 106,723 111,616 106,220 95,402 93,723 98,257 97,311 94,332 91,072
Common stock, par value $1.00 per share 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120 3,120
Accumulated other comprehensive loss (12,527) (8,780) (13,135) (12,626) (12,967) (15,292) (13,843) (13,757) (13,058) (15,415) (15,100) (15,328) (15,242) (14,938) (15,533) (16,243) (15,891) (15,533) (14,969) (15,517)
Retained earnings and Additional paid-in capital 153,843 152,536 129,381 124,558 128,345 127,917 126,216 124,380 123,060 121,092 120,154 116,508 113,890 114,831 113,898 112,901 110,659 109,242 109,809 106,650
Common stock held in treasury, at cost (75,662) (75,648) (44,217) (44,183) (41,694) (41,146) (39,136) (39,034) (39,099) (38,525) (38,594) (38,466) (38,490) (38,540) (38,507) (38,484) (38,417) (38,619) (37,175) (35,298)
Total Johnson & Johnson shareholders’ equity 68,774 71,228 75,149 70,869 76,804 74,599 76,357 74,709 74,023 70,272 69,580 65,834 63,278 64,473 62,978 61,294 59,471 58,210 60,785 58,955
Equity attributable to non-controlling interest 1,260
Total equity 68,774 71,228 76,409 70,869 76,804 74,599 76,357 74,709 74,023 70,272 69,580 65,834 63,278 64,473 62,978 61,294 59,471 58,210 60,785 58,955
Total liabilities and shareholders’ equity 167,558 166,061 191,686 195,969 187,378 175,124 177,724 178,355 182,018 179,228 176,440 172,557 174,894 170,693 158,380 155,017 157,728 155,521 155,117 150,027

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Johnson & Johnson current liabilities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Johnson & Johnson non-current liabilities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Johnson & Johnson total liabilities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Total Johnson & Johnson shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Johnson & Johnson total Johnson & Johnson shareholders’ equity decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.